 Glucagon-Like Peptide 1
"Glucagon-Like Peptide 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
| Descriptor ID |
D052216
|
| MeSH Number(s) |
D06.472.317.469.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide 1".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide 1".
This graph shows the total number of publications written about "Glucagon-Like Peptide 1" by people in this website by year, and whether "Glucagon-Like Peptide 1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2008 | 1 | 1 | 2 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 1 | 3 | | 2011 | 3 | 3 | 6 | | 2012 | 2 | 0 | 2 | | 2013 | 3 | 3 | 6 | | 2014 | 6 | 2 | 8 | | 2015 | 3 | 3 | 6 | | 2016 | 1 | 2 | 3 | | 2017 | 3 | 1 | 4 | | 2018 | 1 | 0 | 1 | | 2019 | 3 | 4 | 7 | | 2020 | 4 | 1 | 5 | | 2021 | 1 | 1 | 2 | | 2022 | 1 | 3 | 4 | | 2023 | 1 | 4 | 5 | | 2024 | 0 | 1 | 1 | | 2025 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucagon-Like Peptide 1" by people in Profiles.
-
Bonaca MP, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Ramesh CK, Rasouli N, Sourij H, Videmark A, Verma S. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025 05 03; 405(10489):1580-1593.
-
Ditzenberger GL, Lake JE, Kitch DW, Kantor A, Muthupillai R, Moser C, Belaunzaran-Zamudio PF, Brown TT, Corey K, Landay AL, Avihingsanon A, Sattler FR, Erlandson KM. Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study. Clin Infect Dis. 2025 02 24; 80(2):389-396.
-
Muschler K, Muschalek R, Hoyte C. Characterization of glucagon-like peptide-1 (GLP-1) agonist exposures reported to a single United States poison center. Clin Toxicol (Phila). 2025 Feb; 63(2):133-136.
-
Bonaca MP, Catarig AM, Hansen Y, Houlind K, Ramesh CK, Ludvik B, Nordanstig J, Rasouli N, Sourij H, Verma S. Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes. Eur Heart J Cardiovasc Pharmacother. 2025 Jan 11; 10(8):728-737.
-
Peters JC, Breen JA, Pan Z, Nicklas J, Cornier MA. A Randomized, Crossover Trial Assessing Appetite, Energy Metabolism, Blood Biomarkers, and Ad Libitum Food Intake Responses to a Mid-Morning Pecan Snack vs. an Equicaloric High-Carbohydrate Snack in Healthy Volunteers with Overweight/Obesity. Nutrients. 2024 Jun 29; 16(13).
-
Park J, Ntelis S, Yunasan E, Downton KD, Yip TC, Munir KM, Haq N. Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2023 12 21; 109(1):279-292.
-
Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity Management in Adults: A Review. JAMA. 2023 11 28; 330(20):2000-2015.
-
Perreault L, Bergman BC. Out of stock: A brief clinical reference for rough equivalency of glucagon-like peptide-1 (GLP-1) ? glucose-dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes. J Diabetes. 2024 Jun; 16(6):e13505.
-
Salahuddin T, Hebbe A, Daus M, Essien UR, Waldo SW, Rodriguez F, Ho PM, Simons C, Gilmartin HM, Doll JA. Trends and site-level variation of novel cardiovascular medication utilization among patients admitted for heart failure or coronary artery disease in the US Veterans Affairs System: 2017-2021. Am Heart J. 2024 02; 268:68-79.
-
Dumolt JH, Rosario FJ, Kramer AC, Horwitz S, Powell TL, Jansson T. Maternal glucagon-like peptide-1 is positively associated with fetal growth in pregnancies complicated with obesity. Clin Sci (Lond). 2023 04 26; 137(8):663-678.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|